Craig Sable, MD, receives the American Heart Association's Heart Vascular Disease in Young (CVDY) 2018 Meritorious Achievement Award [embedded content]…
Craig Sable, MD, receives the American Heart Association’s Heart Vascular Disease in Young (CVDY) 2018 Meritorious Achievement Award
“The cost of a open surgery in Uganda is $ 5,000 to $ 10,000, while treatment for a child with penicillin for one year costs less than $ 1, says Dr Sable. “Investments in preventive strategies have the best promise to extensively eradicate rheumatism heart disease. “
WASHINGTON (PRWEB) November 15, 2018
Craig Sable, MD, Associate Director of the Division of Cardiology and Head of Ecocardiography at the Children‘s National Health System, earned a lifetime achievement, formally known as 2018 Cardiovascular Disease in Young (CVDY) Meritorious Achievement Award, November 10th at American Heart Associations Scientific Sessions 2018.
CVDY Council donates prestige t price to individuals who have a significant impact on cardiovascular disease in young people. The CVDY Council supports the mission to improve child and adult health with congenital heart disease and acquired heart disease during childhood through research, education, prevention and retaliation.
Dr. Sable is acknowledged for his entire research, education and advocacy focused on congenital and acquired heart disease, but especially for his rheumatic heart disease research in Uganda.
Over the past 15 years, Dr Sable has taken over 100 doctors and medical staff to Kampala, the capital and largest city in Uganda, and collaborates with more than 100 local doctors and clinics to develop a template for a sustainable infrastructure to diagnose, treat and prevent both RHD and congenital heart disease.
RHD is a result of cardiac valve damage after acute rheumatic fever (ARF). The process begins with a sore throat from streptococcal infection, which many children in the United States treat with antibiotics.
“For patients who develop streak throat, their body’s reaction to the stiff throat, in addition to solving their primary symptoms, can lead to attacking the heart,” said Dr. Sable. “The initial injuries are called acute rheumatic fever. In many cases, this disease is self-limiting, but if not detected, it can lead to prolonged cardiovascular injury called rheumatic heart disease. Unfortunately, when severe RHD develops, the only treatment is open cardiac surgery. “
In 2017, Sable and the researchers published a study in the New England Journal of Medicine about the global burden of RHD, often called a poverty disease.
RHD is more often observed in low and middle income countries as well as in marginalized communities in high income countries. has decreased globally, but it remains the main cause of sickness and mortality from heart disease in children and young adults worldwide.
In 2017 there were 39.4 million causes of RHD, resulting in 285,000 deaths and 9.4 million
In 2018, the World Health Organization issued a referendum recognizing rheumatic heart disease as an important disease as member states and health ministries must prioritize in their public health efforts.
The common denominator who runs Dr Sable and the global researchers, many of whom have received contributions from the American Heart Association to study RHD, it is Impact that creates a scalable solution, such as the extensive adoption of vaccines, can affect all societies.
“The cost of an open heart surgery in Uganda is $ 5,000 to $ 10,000, while treatment for a child with penicillin for one year costs less than $ 1,” says Dr. Sable. “Investments in preventive strategies have the best promise to a large extent to eradicate rheumatic heart disease. “
Sable and the team have screened more than 100,000 children and conduct the first randomized controlled RHD trial that records nearly 1,000 children to investigate the effectiveness of using penicillin to prevent the progression of latent or subclinical heart disease, the earliest form of RHD.
During Thanksgiving weekend weekend, Dr. Sable and a team of surgeons return to Uganda to work on children affected by RHD while researching their research efforts to produce a scalable solution exported globally to prevent RHD in its earliest stages.
Dr. Sable and colleagues from all over the world a partner in several funded research projects. In the next few years, the team hopes to answer several important issues, including: Does penicillin protect the earliest form of RHD and can we develop a vaccine to prevent RHD?
To view the team’s previously published research, visit Sables PubMed profile.
To learn global health initiatives led by researchers at Children’s National, visit http://www.GHICN.org.
Media Contact: Jessica Frost | 301-828-7521 | 202-476-4500
Jessica Frost Children’s National Health System
Email> Visit Website